Key result
Robotic aortic valve replacement is associated with 0% mortality and improved left ventricular remodeling at 24 months.
Observational (n=15)
Robotic aortic valve replacement demonstrated promising short- and mid-term clinical outcomes with no mortality at 24 months and significant reduction in left ventricular end-diastolic diameter.
Background: Robotic aortic valve replacement (RAVR) has seen a rise in usage in recent years; however, follow-up data remain limited. This study aimed to assess the short- and mid-term clinical outcomes after RAVR. Methods: This study included patients who underwent RAVR between 2022 and 2024. The primary outcomes were mortality and survival at follow-up. The secondary outcomes were hospital complications and echocardiographic parameters at follow-up. Results: Fifteen patients underwent RAVR. The mean age was 38.6±14.4 years, and 86.7% were males. The median Society of Thoracic Surgery (STS) score was 0.6%. Isolated RAVR was performed in 66.7% of the patients (n=10), whereas five patients underwent concomitant surgery, including mitral valve repair (n=1), mitral valve replacement (n=3), and ascending aortoplasty (n=1). Mechanical valves were used in 10 patients (66.7%). The mean ischemic time was 150±33.9 min. No sternotomy conversion was required. The median length of hospital stay was 9 days [quartile (Q)1-Q3, 4-15 days]. Four patients had on-table extubation (26.7%). One patient required intensive care unit (ICU) readmission, and one patient was readmitted for pleural effusion. The median follow-up was 24 months (Q1-Q3, 15-29 months). No mortality was reported during this period. All patients were in New York Heart Association (NYHA) class I, except for one in NYHA II. There were no significant changes in left ventricular ejection fraction (LEVF) at the last follow-up compared with the preoperative value (P=0.741). However, the left ventricular end-diastolic diameter (LVEDD) was significantly lower at follow-up than preoperatively (P=0.003). Conclusions: RAVR demonstrates promising short- and mid-term clinical outcomes. Its minimally invasive nature and the ability to use durable mechanical valves may offer potential advantages over traditional surgical and transcatheter approaches.
No takes yet. Share an insight, caveat, or question.
Khaliel et al. (2025) conducted an observational in Aortic valve disease requiring replacement (n=15). Robotic aortic valve replacement (RAVR) was evaluated on Mortality and survival at follow-up. Robotic aortic valve replacement was associated with 0% mortality over a median 24-month follow-up and a significant reduction in left ventricular end-diastolic diameter (P=0.003).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: